ICM
ANIK icon

Invenomic Capital Management’s Anika Therapeutics ANIK Stock Holding History

Invenomic Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-210,332
Closed -$4.77M – 148
2023
Q4 		$4.77M Buy
210,332
+116,679
+125% +$2.41M 0.22% 112
2023
Q3 		$1.74M Buy
+93,653
New +$1.94M 0.07% 132
2022
Q4 		– Sell
-140,312
Closed -$3.34M – 142
2022
Q3 		$3.34M Sell
140,312
-3,975
-3% -$91.5K 0.29% 98
2022
Q2 		$3.22M Buy
+144,287
New +$3.22M 0.23% 102

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Invenomic Capital Management's ANIK Position: Q1 2024 in Review

Invenomic Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2024, closing a stake of 210,332 shares — an estimated $4.77M sold.

Invenomic Capital Management first reported a position in ANIK in Q2 2022 and held it in 4 quarters. The position peaked at $4.77M in Q4 2023. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2024.

  • Invenomic Capital Management reported no remaining Anika Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 210,332 Anika Therapeutics shares in Q1 2024, an estimated $4.77M.
  • Invenomic Capital Management first reported a position in Anika Therapeutics in Q2 2022 and held it in 4 quarters.
  • Invenomic Capital Management's Anika Therapeutics position peaked at $4.77M in Q4 2023.
  • 120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2024.

Based on Invenomic Capital Management's 13F filing for Q1 2024, filed 15 May 2024.